Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the compound is
3. The compound of claim 1 , wherein the compound is
4. The compound of claim 1 , wherein the compound is
5. The compound of claim 1 , wherein the compound is
6. The compound of claim 1 , wherein the compound is
7. The compound of claim 1 , wherein the compound is
8. The compound of claim 1 , wherein the compound is
9. The compound of claim 1 , wherein the compound is
10. The compound of claim 1 , wherein the compound is
11. The compound of claim 1 , wherein the compound is
12. The compound of claim 1 , wherein the compound is
13. The compound of claim 1 , wherein the compound is
14. The compound of claim 1 , wherein the compound is
15. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
16. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
17. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
18. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
19. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
20. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
21. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
22. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
23. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
24. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
25. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
26. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
27. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is
28. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
29. The pharmaceutical composition of claim 28 , wherein the pharmaceutical composition comprises the compound of claim 1 not as a pharmaceutically acceptable salt.
30. The pharmaceutical composition of claim 28 , wherein the pharmaceutical composition comprises the compound of claim 1 as a pharmaceutically acceptable salt.